

"Is it Sleep Apnea, or ...?"





Remote Attendees, Welcome! Please leave your phones on <u>MUTE</u> – Thank You!





Agenda

8:00-9:15 – The scope of the problem; Benefits of treatment; Definitions; Identifying patients at risk; Establishing the diagnosis; Treatment options

9:15-9:30 Break

9:30-10:30 – Understanding the Equipment

10:30-10:45 Break

10:45 -11:15 – Tracking compliance

11:15-11:30 – Deprescribing

11:30-12:00 – Panel Questions

careoregon.org



Sleep Medicine

Bill Bowerfind, M.D.

The Oregon Clinic, Pulmonary, Critical Care and Sleep Division Medical Director, Providence Portland Medical Center Sleep Disorders Center and Providence Milwaukie Sleep Lab







Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- How to identify patients at risk
- Treatment
- Follow-up





Wake Up!



careoregon.org | page 6



Which has more caffeine?



Monster Energy 16 oz.



Mt. Dew **12 oz.**

160 mg 10 mg/oz. 54 mg 4.5 mg/oz.



Red Bull **8.46 oz.**

80 mg 9.5 mg/oz.



Starbuck's Coffee **8 oz.**

180 mg 22.5 mg/oz.





Caffeine

- Stimulating effect within 15 min of consumption
- Half life of 4-8 hours
 - Can double in later stages of pregnancy
 - Up to 96 hours in acute liver disease
- In some individuals, caffeine can disrupt sleep even 15 hours after ingestion.
- Caffeine withdrawal
 - Occurs within 12-24 hours of discontinuation
 - Peak symptoms at 1-2 days
 - Can last up to nine days.





Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance





OSA Epidemiology

~25 million CPAP users in US



U.S Adult Population 245.2 M

Source: Primary research with experts, U.S. Census (2014), Peppard "Increased Prevalence of Sleep-disordered Breathing in Adults."

© American Academy of Sleep Medicine 2016

~227,000 CPAP users in Portland Metro Area







Diagnosing and Treating All 29.4M Americans with OSA Could Save \$100.1 Billion

Today Where <u>80% of OSA Patients Are Undiagnosed</u>

	\$119.6B	Futu Where <u>No</u> OSA Patient					Indiagnosed	
		Total: \$1 Cost per	62.0B Person: \$5,5	11		: \$61.9B per Person: \$2,105		
\$30.0B						\$61.9B		
		\$12.4B	\$0	\$0	\$0		\$0	
Healthcare Costs	Non- Healthcare Costs	Healthcare Costs	Non- Healthcare Costs	Healthcare Costs	Non- Healthcare Costs	Healthcare Costs	Non- Healthcare Costs	
Undiagnosed		Diagnosed		Undiagnosed		Diagnosed		

Portland, we have a problem...



12% of the CareOregon Population

- We need your help
- Your patients need your help





Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance

OREGON C L I N I C



OSA Treatment has a Major Impact on Comorbidities

After one year, patients surveyed state OSA treatment delivers...



Hypertension

Di

Diabetes

•31% report improved HbA1c •14x increase in "good quality" sleep

•41% report blood pressure improvement

17% report decrease in medication usage



•54% report improved respiratory function
•70% increase in patients reporting symptoms as mild
•8x increase in "good quality" sleep



© American Academy of Sleep Medicine 2016



OSA Treatment has a Major Impact on Comorbidities After one year, patients surveyed state OSA treatment delivers...

ZZZ Insomnia

- •7x increase in good quality sleep
- Decline from 54% to 1% reporting "very bad" quality sleep



12x increase in "good quality" sleep
4x reduction in reported life threatening mental health condition
49% report improved mental health



•56% report reduced heart disease risk

•5x decrease in self-reported life-threatening heart disease

- Decline from 50% to 3% reporting "very bad" quality sleep
- Increase from 0% to 26% reporting "very good" quality sleep

OREGON C L I N I C

© American Academy of Sleep Medicine 2016





Quality of Sleep Across Comorbidities

Before and after sleep apnea treatment

A high proportion of respondents with comorbidities declare their sleep quality as 'good'/ 'very good' after treatment. The biggest difference is among High Blood Pressure patients (79% vs 8% before treatment.) and the smallest among Insomnia patients (65% vs. 8% before treatment.)





Ó

careoregon.org

© American Academy of Sleep Medicine 2016



OREGON C L I N I C

Ø

careoregon.org

r

Cardiovascular/Cerebrovascular Disease

and OSAS



FIGURE 1. Recordings of sympathetic nerve activity, respiration, and intra-arterial blood pressure in an otherwise healthy patient with obstructive sleep apnea (OSA) during wakefulness (top left), during recurrent obstructive apneas (bottom panel), and during treatment with continuous positive airway pressure (CPAP) (top right). Even during wakefulness and normoxia, patients with OSA have high levels of resting sympathetic nerve activity. During obstructive apneas, chemoreflex activation by hypoxemia and hypercapnia causes even further increases in sympathetic activity, with recurrent surges in blood pressure nost notable at the end of apneic events. Blood pressure increases up to 250/130 mm Hg even though the patient is normotensive during wakefulness. Treatment with CPAP lowers both sympathetic activation and blood pressure. REM = rapid eye movement. Reprinted from Somers et al.⁷⁴ with permission from the American Society for Clinical investigation.





OSA Treatment Benefits – The Patient Perspective

- Respondents gained an **additional 1.7 hours** of sleep after treatment
- **11x increase reporting sleep as "good" or "very good"** following treatment with a long-term persistence effect beyond initial adoption
- The percentage of respondents stating their quality of life was "good/very good" tripled (26% vs. 76%) following treatment
- Satisfaction with bed partner relationship, mood and patience **doubled**
- Use of alcohol, cigarettes, and sleeping aids substantially declined post-treatment
- **Productive work time grew 17%** after treatment
- Work absences declined 40% after treatment





Benefits of Treatment: The "Triple Aim"

Beyond economics and cost savings, imagine what the U.S. would be like if all 29.4 million people with OSA received treatment...



•Improved outcomes increases profit in a value-based healthcare system

•Lowers healthcare utilization and reduces admissions



Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment

Definitions

- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance

OREGON C L I N I C











Definitions: Respiratory Events

- Obstructive sleep apnea (OSA)
 - Apnea: No airflow >10 sec, but *continued effort*
 - Hypopnea: Shallow breathing with 4% decline in O2 sat
- Central sleep apnea (CSA)
 - No airflow or effort >10 sec
- Complex sleep apnea
 - OSA that becomes predominately CSA during CPAP
- Upper airway resistance syndrome (UARS)
 - Respiratory effort-related arousals (RERAs)







Obstructive Sleep Apnea







Polysomnography with central sleep apnea (A) and obstructive sleep apnea (B). Chest effort indicated by the arrows is absent in CSA. Reprinted with permission from Grimm and Koehler (2014). CC BY 4.0

Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance





Definitions: Sleep Apnea severity

- Apnea hypopnea index (AHI): Respiratory events/hour
 - < 5 Normal
 - 5-15 Mild Treat if symptoms/comorbidities
 - 15-30 Moderate Treat
 - >30 Severe Treat
- Respiratory disturbance index (RDI)
 - Includes RERAs





Patients at High Risk for OSA

- BMI > 35
- CHF
- Atrial fibrillation
- Refractory hypertension
- Type II DM
- Nocturnal arrythmias
- CVA
- Pulmonary hypertension
- High risk driving population
- Bariatric surgery candidates





Clues to Diagnosis

- Snoring
- Witnessed apneas
- Gasping, choking at night
- Non-refreshing sleep
- Sleepiness (Epworth)
- Nocturia

- Morning headaches
- Decreased concentration
- Memory loss
- Decreased libido
- Irritability





Exam Clues

- Increased BMI
- Retrognathia
- Nasal obstruction
- Narrow oropharynx
- High Mallampati score
- Increased neck circumference
- Cor pulmonale







Mallampati Score





Ø

Tongue Scalloping







STOP BANG Questionnaire

 Snoring Yes No
 Do you snore loudly (louder than talking or loud enough to be heard through closed doors)?

2. *Tired* Yes No

Do you often feel tired, fatigued, or sleepy during daytime?

3. *Observed* Yes No

Has anyone observed you stop breathing during your sleep?

4. Blood *Pressure* Yes No

Do you have or are you being treated for high blood *pressure?*

5. BMI Yes No

BMI more than 35 kg/m2?

6. Age Yes No

Age over 50 yr old?

7. **N**eck circumference

Yes No

Neck circumference greater than 40 cm?

8. *Gender* Yes No *Gender male?*

High risk of OSA: ≥ 3 Low risk of OSA: < 3

The Epworth Sleepiness Scale (ESS)

How likely are you to doze off or fall asleep in the following situations:

- 0 = would never doze
- 1 = slight chance of dozing
- 2 = moderate chance of dozing
- 3 = high chance of dozing
- SITUATION CHANCE OF DOZING (0-3)
- Sitting and reading
- Watching television
- Sitting inactive in a public place (e.g. a theater or meeting)
- As a passenger in a car for an hour without a break
- Lying down to rest in the afternoon when circumstances permit
- Sitting and talking to someone
- Sitting quietly after a lunch without alcohol
- In a car, while stopped for a few minutes in the

traffic

≥10 = significant sleepiness



STOP BANG and Epworth

STOP BANG Questionnaire

heard through closed doors)?

1. Snoring

Yes No Do you snore loudly (louder than talking or loud enough to be

2. Tired Yes No

Do you often feel tired, fatigued, or sleepy during daytime?

3. Observed Yes No

Has anyone observed you stop breathing during your sleep?

4. Blood *pressure* Yes No

Do you have or are you being treated for high blood pressure?

5. BMI Yes No

BMI more than 35 kg/m2?

Yes No 6. Age

Age over 50 yr old?

7. Neck circumference Yes No

Neck circumference greater than 40 cm?

8. Gender Yes No Gender male?

High risk of OSA: answering yes to three or more items Low risk of OSA: answering yes to less than three items

The Epworth Sleepiness Scale (ESS)

How likely are you to doze off or fall asleep in the following situations:

0 = would never doze

1 = slight chance of dozing

2 = moderate chance of dozing

3 = high chance of dozing

SITUATION CHANCE OF DOZING (0-3)

- Sitting and reading .
- Watching television
- Sitting inactive in a public place (e.g. a theater or meeting)
- As a passenger in a car for an hour without a break
- Lying down to rest in the afternoon when circumstances permit
- Sitting and talking to someone ٠
- Sitting guietly after a lunch without alcohol
- In a car, while stopped for a few minutes in the traffic

10 or greater is significant sleepiness





STOP BANG

- All items: yes or no
 - High risk of OSAS if yes to 3+ questions
 - Low risk if yes to < 3 questions
- Sensitivity
 - AHI <u>></u> 5: 84%
 - AHI <u>></u> 15: 93%
 - AHI <u>></u> 30: 100%
- Specificity
 - AHI <u>></u> 5: 56%
 - AHI <u>></u> 15: 43%
 - AHI <u>></u> 30: 37%





Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance





Types of Studies

- Split Night Polysomnogram
- Home Sleep Test (HST)
 - Type 3
 - WatchPAT
- PAP Titration
- Auto-Titrating PAP




Pre-study Considerations

- Discourage napping, sleeping in on day of study
- Discourage caffeine
- What about alcohol?





The Sleep "Lab"







The Sleep "Lab"





careoregon.org



Split-night Polysomnogram

Advantages:

- Gold standard test
- Direct referral option
- Diagnostic followed by CPAP titration if criteria met
- 16 channel *attended* study
- Activity noted and recorded
- Sleep is scored

Disadvantages:

- In-lab, may inhibit sleep
- Cost



















Home Sleep Apnea Test (HST)

- Application of sensors by sleep tech or patient
- Sole indication is diagnosis of OSAS
 - Attended/full PSG is *mandatory* if HSAT is non-diagnostic
 - False negative rate up to 17%
 - Not a screening tool; not able to "rule out" OSAS
- Other uses

PSG not practical due to immobility, safety Monitor response to non-CPAP treatments





HST Exclusion Criteria

- EPWORTH < 10, STOP BANG < 3
- Heart Disease

Congestive Heart Failure

- Acute or chronic
- Diastolic and/or systolic

MI (myocardial infarction)

Coronary Artery Disease

Heart Arrhythmia

Atrial Fibrillation

Congestive Heart Failure (CHF)

Pacemaker Right heart failure

- Stroke
- Lung Disease COPD Pulmonary fibrosis
- Restrictive lung disease
- Oxygen Dependence
- BMI > 50
- Cognitive Impairment

Neuromuscular disease

ALS

•

Post polio

Kyphoscoliosis

Muscular dystrophy

Parkinson's

MS

Myasthenia Gravis

Guillain Barre

- Insomnia
- Parasomnia- known or suspected
- Circadian rhythm disorders
- Pulmonary hypertension
- Vascular Disease
- Pain Medications- Morphine/MS Contin; Oxycodone/Oxycontin; Dilaudid, and/or Methadone
- Stimulant medications- Adderall/methamphetamine; Ritalin/methylphenidate





HST



- Advantages:
 - Available for home dx
 - Less interference with sleep (?)
 - Less costly
- Disadvantages
 - Diagnostic only, No split study
 - Not attended, not monitored
 - No documentation of sleep/EEG
 - Can not detect UARS
 - Significant failure rate (10-20%)
- Pro/Con: Requires Sleep Consult







*Poor choice in patients with insomnia





WatchPAT

- Wrist-mounted home sleep test
- Measures:
 - PAT (peripheral arterial tone)
 - Oximetry
 - Actigraphy
 - Heart Rate
 - Body Position
 - Snoring

• Measures sleep and respiratory events







WatchPAT: Advantages

- Easy instructions for patient
- Less interruption of sleep (not proven)
- Option of "chain of custody"







WatchPAT NOT for Everyone

- Consider if: High likelihood of moderate-severe OSA
- Inappropriate for:
 - Suspected central sleep apnea
 - Significant CHF
 - Moderate to severe lung disease
 - Neuromuscular disease
 - Insomnia
- In addition, avoid use if:
 - Medications: alpha blockers (doxazosin/Cardura) and nitrates
 - Permanent pacemaker
 - Sustained non-sinus rhythm (ex.: A.Fib)
 - Peripheral Vascular Disease
 - PLMS/RLS





Pearls of HST

- ONLY for patients with:
 - HIGH pretest likelihood of OSA
 - No contraindications
- Good for RULING OSA IN
- Does NOT rule out OSA

<u>A negative HST should be followed by an in-lab PSG</u>





Obstructive Sleep Apnea

- The scope of the problem
- Benefits of treatment
- Definitions
- Identifying patients at risk
- Establishing the diagnosis
- Treatment options
- Tracking compliance











OSAS - Treatment

- Weight loss
- Oral appliances
 - Mandibular repositioning
 - Continuous Open Airway Therapy (COAT)
 - Mild to moderate OSAS
 - Patient preference over CPAP
 - Do not respond to or fail CPAP
 - Not appropriate candidates for CPAP
 - American Academy of
 - **Dental Sleep Medicine**
 - (AADSM)







Oral Appliances: Side Effects

- Jaw pain, TMJ
- Malocclusion
- Excessive salivation
- Tooth migration
- Inadequate treatment





Treatment

- Surgery
 - Often first line therapy in children
 - Tonsils/adenoids
 - Mixed (but generally disappointing) results in adults
 - Uvulopalatopharyngoplasty (UPPP)
 - Maxillomandibular advancement (MMA)
- Positional Therapy
 - SlumberBump







Types of Positive Airway Pressure

- CPAP: Continuous, single pressure
- BPAP: Bilevel. Higher inspiratory pressure, lower pressure during exhalation.
- BPAP ASV: Adaptive servo ventilation
 - For central and complex sleep apnea
- BPAP AVAPS: Average volume assured pressure support
 - For neuromuscular disease
 - Targets a predetermined tidal volume.
- Auto titrating CPAP/BiPAP











careoregon.org



CPAP Titration Options

In-lab titration

- Identical set up to diagnostic study
- Single night
- Technician present
 - Reassurance
 - Trouble shooting
- Ability to try different masks
- Expensive

Auto-CPAP titration

- Done at home
- Worn for ~30 days
- Patient responsible for identifying/reporting issues
- Difficult to trial masks
- Less expensive





In-Lab CPAP Titration

- Patients with significant desaturations
- Positional or sleep stage dependent sleep apnea
- Narcotics
- Concern for complex sleep apnea
- Failed auto-CPAP
- Reluctant patient
- To assess response of other issues to therapy





Auto-Titrating CPAP (APAP)

- Can be used at home to determine
 - Optimal fixed level of CPAP, in patients without significant comorbidities/hypoxemia
 - Follow-up CPAP pressure adjustment (weight change, sxs)
 - As final treatment mode
- Provider sets CPAP range (5-20 cmH2O)
- Monitors snoring, airflow and flow vs time.
- Proprietary algorithm varies pressure as needed.
- "Optimal" CPAP pressure is 90%







Auto-Titrating CPAP

Patient requirements:

- Reliable, competent
- Accepting of CPAP
- Well educated on using CPAP
- Have a good mask fit
- Able to reliably apply the mask properly **Physician requirements:**
- Timely follow-up of results
- Responsive to CPAP related issues
- Know how to review results.





Initiating Therapy

- Review study results, severity.
- Emphasize benefits to symptoms and comorbidities
- May take time to get this right
 - Mask size, type
 - Pressure setting
 - Leaks
- Wear it every night
- Try wearing while watching TV or otherwise distracted
- Call DME with issues
- Consider sleep tech visit, sleep consult









What Happens Next? Understanding the Equipment Heather Stoecklin, RRT Population Health Respiratory Therapist CareOregon

Shannon Kaski, RPSGT Sleep Center Manager, The Oregon Clinic







Where Does the Equipment Come From ?

- Several DME companies provide the equipment prescribed after a sleep study.
- You can choose any company that you feel gives the best service to your patient.
- These companies also provide oxygen, nebulizers and other respiratory equipment.
- Consider keeping all equipment with the same company whenever possible.
- Consider narrowing down the companies that you use to promote a relationship between your staff and the DME company.



It can be very difficult for patients to adjust to using sleep equipment. It doesn't mean that they are doing something wrong.

They often need a lot of support in the beginning.





Clinic Champions

- Clinic Champions Pilot
- Shadow OC providers & DME staff
- Exciting model for primary care

Why become a Champion?



MA PAP Issue Reference Sheet

(see your handout)

Please let the patients know that you will need to gather the necessary information to pass on to the patient's provider and/or the sleep center for recommendations.

If at any point you feel it would be best for patient to speak with a sleep technologist, please direct them to the sleep lab that performed the test or to the DME provider.



Mask Discomfort

- Which style mask do they use? (nasal pillow, nasal, full face)
- Where is the discomfort?
- When did the discomfort start?
- Have they tried adjusting the mask/headgear?
- How is it affecting their amount of usage?
- How long has it been since they have gotten a new mask?



Mask Leak

- Which style mask do they use? (nasal pillow, nasal, full face)
- Where is the mask leaking?
- Have they tried adjusting the mask/headgear?
- How long has it been since they have gotten a new mask?
- How often are they cleaning their current mask?



Too Much Pressure

- Are they having difficulties exhaling out against the pressure?
- Is it difficult to get the mask to seal?
- Do they experience any pressure/discomfort in their ears?
- Do they feel like they are swallowing air?
- Do they use the ramp button?



Not Enough Pressure

- Is it a comfort issue (like they are "starving for air")?
- Does bed partner notice snoring or breathing pauses?
- Does patient wake gasping for air?


Common Problems When Adjusting to Sleep Equipment

Nasal/Oral Dryness

- Which style mask do they use? (nasal pillow, nasal, full face)
- If nasal pillows or nasal mask, do they use a chin strap?
- Do they use their heated humidity? If so, do they know what it is set at?
- Are they using all of the water in their humidifier each night?



Common Problems When Adjusting to Sleep Equipment

Condensation in Tubing/Mask

- What is their humidifier set at?
- Have they tried adjusting the setting?
- Is their tubing insulated?



Common Problems When Adjusting to Sleep Equipment

Replacement Equipment

- If patient needs a replacement mask/cushion, tubing, filters, etc., please refer them to their DME company.
- If patient complains of a broken machine, refer them to their DME company.



PAP Cleaning & Resupply Schedule

It is important to follow the replacement and cleaning recommendations below to ensure effective treatment and avoid damage to equipment.

SUPPLY ITEM	CLEANING SCHEDULE	REPLACEMENT SCHEDULE
Full Face Cushion	Daily	1 per month
Nasal Cushion	Daily	2 per month
Nasal Pillow Cushion	Daily	2 per month
PAP Mask	Weekly or sooner if visibly dirty	1 per 3 months
PAP Headgear	Bi-Weekly or sooner if visibly dirty	1 per 6 months
Chinstrap	Monthly or sooner if visibly dirty	1 per 6 months
PAP Tubing	Weekly	1 per 3 months
Disposable Filter	N/A	2 per 1 month
Non-disposable Filters	Monthly	1 per 6 months
Humidifier Chamber	Weekly	1 per 6 months

careoregon.org | page 76 For replacement supplies please contact your DME Company.

































Tracking Compliance

Bill Bowerfind, M.D.

The Oregon Clinic, Pulmonary, Critical Care and Sleep Division Medical Director, Providence Portland Medical Center Sleep Disorders Center and Providence Milwaukie Sleep Lab







Follow-up – Compliance

- Ideally, contact patient in first several days after starting CPAP.
- Face to face follow up with prescribing provider 30-90 days after initiating therapy
- Review compliance download.
- Compliance = Usage for >4 hours/day on 70% of days.
- Ensure symptom resolution
- Trouble-shoot issues





PAP Compliance Downloads

- PAP compliance download within 30–90 days of initiating therapy.
- Arrange for download on-line.
- If patients are having any issues with CPAP mask, tubing or machine have them bring equipment to the appointment.





6/14/2019 - 7/13/2019



7 mins, 34 secs.

5.7

Compliance Summary Date Range 6/14/2019 - 7/13/2019 (30 days) Days with Device Usage 30 days Days without Device Usage 0 days Percent Days with Device Usage 100.0% Cumulative Usage 10 days 8 hrs. 40 mins. 51 secs. Maximum Usage (1 Day) 10 hrs. 13 mins. 45 secs. Average Usage (All Days) 8 hrs. 17 mins. 21 secs. Average Usage (Days Used) 8 hrs. 17 mins. 21 secs. Minimum Usage (1 Day) 6 hrs. 35 mins. 1 secs. Percent of Days with Usage >= 4 Hours 100.0% 0.0% Percent of Days with Usage < 4 Hours Total Blower Time 10 days 8 hrs. 41 mins. 7 secs. Auto-CPAP Summary Auto-CPAP Mean Pressure 7.5 cmH2O Auto-CPAP Peak Average Pressure 9.1 cmH2O Average Device Pressure <= 90% of Time 8.5 cmH2O



Average AHI

Average Time in Large Leak Per Day



Barney

Device Settings as of	7/13/2019	
Device Mode	AutoCPAP - A-Flex	
Device Settings		
Parameter		Value
Min Pressure		7 cmH2O
Max Pressure		20 cmH2O
A-Flex Setting		2
Auto Off		Off
Auto On		Off
View Optional Screens		On
Ramp Type		Linear
Ramp Time		20 minutes
Ramp Start Pressure		5.0 cmH2O
Mask Resistance		Off
Mask Resistance Lock		Off
Tubing Type		15 HT
Tubing Type Lock		Off
Opti-Start		Off
EZ-Start		Disabled
Tube Temperature		3
Humidifier		3
Humidification Mode on Heate	ed Tube Disconnect	Adaptive













Done



Patient with Poor Compliance

- Significant improvement requires >4 hours/ night
- Encourage PAP use during the day while watching TV, reading or otherwise distracted.
- Consider consultation with sleep tech for desensitization
- Consider alternative masks



New Sleep Consults

- If the patient has had a sleep study then we need a copy.
- If the patient is currently on PAP therapy then they need to bring their machine





Appropriate Indications for a Sleep Study

- EXCESSIVE DAYTIME SLEEPINESS
 - Epworth ≥ 10
- Snoring, witnessed apneas, gasping/choking
 - STOP BANG \geq 3
- Insomnia with symptoms above
- Bariatric surgery candidate
- On narcotics, concern for central apnea In-lab study only.





Sleep Study NOT Indicated

- Insomnia alone.
 - Review other causes first.
- Restless legs alone
 - Treat
- Intolerant of CPAP
 - Review download
 - Refer to DME provider
 - Consider acclimation
- CPAP machine not working Refer to DME

- Patient needs
 - new mask or machine
 - Refer to DME
- X years since last sleep study, patient doing fine.

• When in doubt, consider sleep consult.





Consult Recommended

- Home sleep apnea test
- Parasomnias
 - Sleep walking, night terrors, possible seizure, unusual behavior during sleep
- Persistent insomnia
- Narcolepsy
- Idiopathic hypersomnia

- Circadian rhythm disorders
- Complex sleep apnea
- Central sleep apnea
- Not sure what it is or what to do
- I don't feel comfortable dealing with it

















Drowsy Driving

NSF poll on driving to work drowsy

- 27% drive drowsy at least a few days per month
- 12% a few days per week
- 4% every day

- NHTSA: 20% of all auto accidents in US due to driver fatigue
 - 100,000 MVAs
 - 1,550 deaths
- National Sleep Foundation: 36% admit to falling asleep behind the wheel of a moving vehicle





DROWSY IS RED ALERT

- Yawning, rubbing eyes, blinking frequently
- Trouble focusing, keeping eyes open, head up
- Difficulty remembering the last few miles driven
- Drifting from your lane, hitting rumble strips
- Slower reaction time

PULL OVER IMMEDIATELY





Is It Time to Think About Deprescribing? But, how? And, where do I start?

Mariah Alford, PharmD, BCPS Pharmacy Clinical Supervisor CareOregon





Example Medication List:

- Metformin ER 2g once daily
- Glipizide 5mg BID
- ASA 81mg once daily
- Amlodipine 10mg QD
- Lisinopril 20mg QD
- Gabapentin 600mg TID
- Zolpidem 10mg QHS
- Hydrocodone/APAP 5/325 2 tabs QID PRN

- Cyclobenzaprine 10mg TID PRN
- Wixela Inhub (generic Advair) 250/50 1 puff BID
- Incruse Elipta 1 inhalation daily
- Cetirizine 10mg QHS
- Montelukast 10mg QHS
- Clonazepam 0.5mg BID PRN
- Sertraline 100mg once daily



Risk Factors for Polypharmacy

Polypharmacy defined: regular use of five or more medications

Risk factors:

- Patient
- Age >62
- Cognitive impairment
- Developmental disability
- Frailty
- Lack of PCP
- Mental health conditions
- Multiple Chronic conditions
- Residing in a long-term care facility
- Care from multiple subspecialists



Deprescribing Defined:

- The planned process of reducing or stopping medications that may no longer be of benefit or may be causing harm.
- The goal is to reduce medication burden or harm while improving quality of life.

Source: deprescribing.org



How do I Identify Potentially Inappropriate Medications?

- STOPP (screening tool of older people's prescriptions)
- Beers Criteria

AGS 2019 Beers Criteria Update, J Am Geriatr Soc. 2019 Apr;67(4):674-694

STOPP/START criteria for potentially inappropriate prescribing in older people: version 2, Age Ageing. 2018 May; 47(3): 489.

Table 9. Medications/Criteria Added Since 2015 American Geriatrics Society Beers Criteria[®]

Medication/Criterion	Reason for Addition
Rivaroxaban	Emerging evidence of increased risk of serious bleeding compared with other anticoagulant options
Tramadol	Risk of SIADH/hyponatremia
Opioids + gabapentin/pregabalin	Increased risk of overdose

Okay, I'm Ready. How Do I Approach Deprescribing?

- Shared decision making with the patient and/or caregiver
 - An ongoing process that will take time
- Focus on optimizing clinical outcomes within the context of the patient's care goals, level of function, life expectancy, values and preferences

Source: American Family Physician Volume 100, Number 1, July 1, 2019



deprescribing.org Benzodiazepine & Z-Drug (BZRA) Deprescribing Algorithm

Why is patient taking a BZRA? If unsure, find out if history of anxiety, past psychiatrist consult, whether may have been started in hospital for

sleep, or for grief reaction.

 Insomnia on its own OR insomnia where underlying comorbidities managed For those ≥ 65 years of age: taking BZRA regardless of duration (avoid as first line therapy in older people) For those 18-64 years of age: taking BZRA > 4 weeks

Engage patients (discuss potential risks, benefits, withdrawal plan, symptoms and duration)

Recommend Deprescribing

Taper and then stop BZRA

(taper slowly in collaboration with patient, for example \sim 25% every two weeks, and if possible, 12.5% reductions near end and/or planned drug-free days)

- For those ≥ 65 years of age (strong recommendation from systematic review and GRADE approach)
- · For those 18-64 years of age (weak recommendation from systematic review and GRADE approach)
- · Offer behavioural sleeping advice; consider CBT if available (see reverse)

Monitor every 1-2 weeks for duration of tapering

Expected benefits:

+ May improve alertness, cognition, daytime sedation and reduce falls

Withdrawal symptoms:

 Insomnia, anxiety, irritability, sweating, gastrointestinal symptoms (all usually mild and last for days to a few weeks)

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission.
© OSOD This work is licensed under a Creative Commons Attribution-NonCommercial ShareAlike 4.0 International License,
and a dependent of the author of the

Pottie K, Thompson W, Davies S, Grenier J, Sadowshi Cartello V, Hull dok A, Boyd C, Swenson JR, Ma A, Farrell B. Evidence-based clinical practice guideline for deprescribing beruzodiazepine receptor agonists. Can Fam Physician 2018;64:339 51 (Eng), e209 24 (Fr) Other sleeping disorders (e.g. restless legs)

 Unmanaged anxiety, depression, physical or mental condition that may be causing or aggravating insomnia
 Benzodiazepine effective specifically for anxiety

February 2019

Alcohol withdrawal

Continue BZRA

- Minimize use of drugs that worsen insomnia (e.g. caffeine, alcohol etc.)
- Treat underlying condition
- Consider consulting psychologist or psychiatrist or sleep specialist

If symptoms relapse:

Consider

 Maintaining current BZRA dose for 1-2 weeks, then continue to taper at slow rate

Alternate drugs

 Other medications have been used to manage insomnia. Assessment of their safety and effectiveness is beyond the scope of this algorithm. See BZRA deprescribing guideline for details.

Bruyère 👌

This algorithm and accompanying advice support recommendations in the NICE guidance on the use of zaleplon, zdpidem and zopiclone for the short term management of insomnia, and medicines optimisation. National institute for itselfs and Care Excellence, February 2019



Use non-drug

approaches to

Use behavioral

approaches

and/or CBT

(see reverse)

manage

insomnia





deprescribing.org Benzodiazepine & Z-Drug (BZRA) Deprescribing Notes

BZRA Availability

BZRA	Strength
Alprazolam (Xanax®) ^T	0.25 mg, 0.5 mg, 1 mg, 2 mg
Bromazepam (Lectopam®)™	1.5 mg, 3 mg, 6 mg
Chlordiazepoxide ^c	5 mg, 10 mg, 25 mg
Clonazepam (Rivotril®) ^T	0.25 mg, 0.5 mg, 1 mg, 2 mg
Clorazepate (Tranxene®) c	3.75 mg, 7.5 mg, 15 mg
Diazepam (Valium®) [⊤]	2 mg, 5 mg, 10 mg
Flurazepam (Dalmane®) ^c	15 mg, 30 mg
Lorazepam (Ativan®) TS	0.5 mg, 1 mg, 2 mg
Nitrazepam (Mogadon®) [⊤]	5 mg, 10 mg
Oxazepam (Serax [®]) [⊤]	10 mg, 15 mg, 30 mg
Temazepam (Restoril®) ^c	15 mg, 30 mg
Triazolam (Halcion®) [™]	0.125 mg, 0.25 mg
Zopiclone (Imovane®, Rhovane®) ^T	5mg, 7.5mg
Zolpidem (Sublinox®) s	5mg, 10mg

T = tablet, C = capsule, S = sublingual tablet

BZRA Side Effects

• BZRAs have been associated with:

- physical dependence, falls, memory disorder, dementia, functional impairment, daytime sedation and motor vehicle accidents
- Risks increase in older persons

Engaging patients and caregivers

Patients should understand:

- The rationale for deprescribing (associated risks of continued BZRA use, reduced long-term efficacy)
- Withdrawal symptoms (insomnia, anxiety) may occur but are usually mild, transient and short-term (days to a few weeks)
- They are part of the tapering plan, and can control tapering rate and duration

Tapering doses

- · No published evidence exists to suggest switching to long-acting BZ RAs reduces incidence of withdrawal symptoms or is more effective than tapering shorter-acting BZRAs
- If dosage forms do not allow 25% reduction, consider 50% reduction initially using drug-free days during latter part of tapering, or switch to lorazepam or oxazepam for final taper steps

Behavioural management

Primary care:

- 1. Go to bed only when sleepy
- 2. Do not use bed or bedroom for anything but sleep (or intimacy)
- 3. If not asleep within about 20-30 min at the beginning of the night or after an awakening, exit the bedroom
- 4. If not asleep within 20-30 min on returning to bed, repeat #3
- 5. Use alarm to awaken at the same time every morning
- Do not nap
- 7. Avoid caffeine after noon
- 8. Avoid exercise, nicotine, alcohol, and big meals within 2 hrs of bedtime

Using CBT

What is cognitive behavioural therapy (CBT)?

 CBT includes 5-6 educational sessions about sleep/insomnia, stimulus control, sleep restriction, sleep hygiene, relaxation training and support

Does it work?

CBT has been shown in trials to improve sleep outcomes with sustained long-term benefits

Who can provide it?

 Clinical psychologists usually deliver CBT, however, others can be trained or can provide aspects of CBT education: self-help programs are available

How can providers and patients find out about it?

Some resources can be found here: https://mysleepwell.ca/

© Use freely, with credit to the authors. Not for commercial use. Do not modify or translate without permission. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Contact deprescribing@bruyere.org or visit deprescribing.org for more information.

Pottie K, Thompson W, Davies S, Grenier J, Sadowski C, Welch V, Holbrook A, Boyd C, Swenson JR, Ma A, Farrell B, Evidence-based clinical practice guideline for deprescribing benzodiazepine receptor agonists. Can Fam Physician 2018;64:330-51 (Eng), e200-24 (Fr) This algorithm and accompanying advice support recommendations in the NICE guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia, and medicines optimisation. National Institute for Health and Care Excellence, February 2019



Institutional care:

1. Pull up curtains during the day to obtain bright light exposure

February 2019

- 2. Keep alarm noises to a minimum
- Increase daytime activity & discourage daytime sleeping
- 4. Reduce number of naps (no more than 30 mins and no naps after 2 pm)
- 5. Offer warm decaf drink, warm milk at night
- 6. Restrict food, caffeine, smoking before bedtime
- 7. Have the resident toilet before going to bed
- 8. Encourage regular bedtime and rising times

Bruvère 👌

- Avoid waking at night to provide direct care
- 10. Offer backrub, gentle massage

Wait, How Can I Evaluate If I'm Adding the Right Medications in the Future?

• START (Screening Tool to Alert to Right Treatment)

http://medstopper.com/

• START/STOPP & Beers Criteria combined!

https://www.healthinaging.org/medications-older-adults

• Lowest dose for the shortest time



Panel Questions & Answers



Join Our Upcoming Sessions!

- Empowering Patients in Advanced Illness
- Trauma-Informed Care and SUD




Thank you!





Appendix





OREGON Case of Birth:				Summary Report
Date of Birth:	Location:	The Oregon Clinic Sleep T	Setup Date:	6/5/2019
CLINIC Patient Reference:	Address:	1111 NE 99th Ave	Date Range:	6/14/2019 - 7/13/2019
Patient ID:		Portland, OR 97220	Madi:	
Phone Number:	Phone Number:	503-963-3185		
Device:	Undemotation Auto CPAP V1.1.8.3313 (500X110) 2	2459294783CA		

Care Team

Olsen, Esther	The Oregon Clinic Sleep Therapy Services	1111 NE 99th Ave, Portland, OR 97220	503-963-3185
Friberg, PA, Whitni	The Oregon Clinic Pulmonary and Sleep Med Division	1111 NE 99th Ave, Portland, OR 97220	

Compliance Information

6/14/2019 - 7/13/2019

A-Flex"

Compliance Summary

Date Range	6/14/2019 - 7/13/2019 (30 days)
Days with Device Usage	30 days
Days without Device Usage	0 days
Percent Days with Device Usage	100.0%
Cumulative Usage	10 days 8 hrs. 40 mins. 51 secs.
Maximum Usage (1 Day)	10 hrs. 13 mins. 45 secs.
Average Usage (All Days)	8 hrs. 17 mins. 21 secs.
Average Usage (Days Used)	8 hrs. 17 mins. 21 secs.
Minimum Usage (1 Day)	6 hrs. 35 mins. 1 secs.
Percent of Days with Usage >= 4 Hours	100.0%
Percent of Days with Usage < 4 Hours	0.0%
Total Blower Time	10 days 8 hrs. 41 mins. 7 secs.
Auto-CPAP Summary	
Auto-CPAP Mean Pressure	7.5 cmH20
Auto-CPAP Reak Average Pressure	9.1 cmH20
Average Device Pressure <= 90% of Time	8.5 cmH20
Average Time in Large Leak Per Day	7 mins. 34 secs
Average AHI	5.1

Device Settings as of	7/13/2019	
Device Mode Aut	oCPAP - A-Flex	
Device Settings		
Parameter		Value
Min Pressure		7 cmH2O
Max Pressure		20 cmH2O
A-Flex Setting		2
Auto Off		Off
Auto On		Off
View Optional Screens		On
Ramp Type		Linear
Ramp Time		20 minutes
Ramp Start Pressure		5.0 cmH2O
Mask Resistance		Off
Mask Resistance Lock		Off
Tubing Type		15 HT
Tubing Type Lock		Off
Opti-Start		Off
EZ-Start		Disabled
Tube Temperature		3
Humidifier		3
Humidification Mode on Heated Tube	Disconnect	Adaptive
Hours of Usage		
which is a second se		1
20 - Average Flex: 2.0, Last Set	ing: 2.0	
15 Auto CPAP with A-Flex		

Device Humidification Settings

10

Heated Tube Temperature











OREGON Case of Birth:				Summary Report
Date of Birth:	Location:	The Oregon Clinic Sleep T	Setup Date:	6/5/2019
CLINIC Patient Reference:	Address:	1111 NE 99th Ave	Date Range:	6/14/2019 - 7/13/2019
Patient ID:		Portland, OR 97220	Madi:	
Phone Number:	Phone Number:	503-963-3185		
Device:	Undemotation Auto CPAP V1.1.8.3313 (500X110) 2	2459294783CA		

Care Team

Olsen, Esther	The Oregon Clinic Sleep Therapy Services	1111 NE 99th Ave, Portland, OR 97220	503-963-3185
Friberg, PA, Whitni	The Oregon Clinic Pulmonary and Sleep Med Division	1111 NE 99th Ave, Portland, OR 97220	

Compliance Information

6/14/2019 - 7/13/2019

A-Flex"

Compliance Summary

Date Range	6/14/2019 - 7/13/2019 (30 days)
Days with Device Usage	30 days
Days without Device Usage	0 days
Percent Days with Device Usage	100.0%
Cumulative Usage	10 days 8 hrs. 40 mins. 51 secs.
Maximum Usage (1 Day)	10 hrs. 13 mins. 45 secs.
Average Usage (All Days)	8 hrs. 17 mins. 21 secs.
Average Usage (Days Used)	8 hrs. 17 mins. 21 secs.
Minimum Usage (1 Day)	6 hrs. 35 mins. 1 secs.
Percent of Days with Usage >= 4 Hours	100.0%
Percent of Days with Usage < 4 Hours	0.0%
Total Blower Time	10 days 8 hrs. 41 mins. 7 secs.
Auto-CPAP Summary	
Auto-CPAP Mean Pressure	7.5 cmH20
Auto-CPAP Reak Average Pressure	9.1 cmH20
Average Device Pressure <= 90% of Time	8.5 cmH20
Average Time in Large Leak Per Day	7 mins. 34 secs
Average AHI	5.1

Device Settings as of	7/13/2019	
Device Mode Aut	oCPAP - A-Flex	
Device Settings		
Parameter		Value
Min Pressure		7 cmH2O
Max Pressure		20 cmH2O
A-Flex Setting		2
Auto Off		Off
Auto On		Off
View Optional Screens		On
Ramp Type		Linear
Ramp Time		20 minutes
Ramp Start Pressure		5.0 cmH2O
Mask Resistance		Off
Mask Resistance Lock		Off
Tubing Type		15 HT
Tubing Type Lock		Off
Opti-Start		Off
EZ-Start		Disabled
Tube Temperature		3
Humidifier		3
Humidification Mode on Heated Tube	Disconnect	Adaptive
Hours of Usage		
which is a second second		1
20 - Average Flex: 2.0, Last Set	ing: 2.0	
15 Auto CPAP with A-Flex		

Device Humidification Settings

10

Heated Tube Temperature









Betty

Compliance Summary	
Date Range	6/14/2019 - 7/13/2019 (30 days)
Days with Device Usage	26 days
Days without Device Usage	4 days
Percent Days with Device Usage	86.7%
Cumulative Usage	5 days 9 hrs. 44 mins. 42 secs.
Maximum Usage (1 Day)	7 hrs. 19 mins. 54 secs.
Average Usage (All Days)	4 hrs. 19 mins. 29 secs.
Average Usage (Days Used)	4 hrs. 59 mins. 24 secs.
Minimum Usage (1 Day)	1 hrs. 40 mins. 30 secs.
Percent of Days with Usage >= 4 Hours	70.0%
Percent of Days with Usage < 4 Hours	30.0%
Total Blower Time	5 days 9 hrs. 49 mins. 12 secs.
Auto-CPAP Summary	
Auto-CPAP Mean Pressure	11.6 cmH2O
Auto-CPAP Peak Average Pressure	14.1 cmH2O
Average Device Pressure <= 90% of Time	12.7 cmH2O
Average Time in Large Leak Per Day	5 mins. 42 secs.
Average AHI	3.0







Auto-CPAP Download

Summary of Daily Events Per Hour

Total AHI: 4.0

2/5/201	4 - 3/6/2	2014															
Р	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
MaP	0.2	3,440.5	1,794.0	795.3	773.7	661.3	350.8	229.1	219.4	79.4	48.6	21.5	0.0	0.0	0.0	0.0	0.0
%	0.0	40.9	21.3	9.5	9.2	7.9	4.2	2.7	2.6	0.9	0.6	0.3	0.0	0.0	0.0	0.0	0.0
FL	0.0	0.7	0.5	0.9	0.8	0.3	0.7	1.0	0.8	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VS	0.0	3.3	4.8	9.6	8.7	7.6	8.4	13.1	8.8	15.1	11.1	41.8	0.0	0.0	0.0	0.0	0.0
0A	0.0	1.3	1.5	1.7	2.2	2.2	1.4	2.9	2.2	3.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0
CA	0.0	0.1	0.1	0.5	0.2	0.4	0.5	0.8	1.6	0.8	1.2	2.8	0.0	0.0	0.0	0.0	0.0
Н	0.0	1.1	2.0	4.3	4.6	4.5	1.0	0.5	0.5	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0
RE	0.0	0.2	0.6	1.3	0.9	0.8	0.5	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AHI	0.0	2.5	3.6	6.5	7.0	7.1	2.9	4.2	4.3	3.8	4.9	2.8	0.0	0.0	0.0	0.0	0.0
						90%											

Legend P - Pressure, MaP - Minutes at Pressure, % - Percent of Night, FL - Flow Limitation, VS - Vibratory Snore, H - Hypopnea, OA - Obstructed Airway Apnea, CA - Clear Airway Apnea, RE - RERA, AHI - Apnea/Hypopnea Index

Auto CPAP Time at Pressure

2/5/2014 - 3/6/2014









6/15/2019 - 7/14/2019



Compliance Summary	
Date Range	6/15/2019 - 7/14/2019 (30 days)
Days with Device Usage	24 days
Days without Device Usage	6 days
Percent Days with Device Usage	80.0%
Cumulative Usage	2 days 20 hrs. 8 mins. 46 secs.
Maximum Usage (1 Day)	5 hrs. 43 mins. 6 secs.
Average Usage (All Days)	2 hrs. 16 mins. 17 secs.
Average Usage (Days Used)	2 hrs. 50 mins. 21 secs.
Minimum Usage (1 Day)	1 hrs. 3 mins. 20 secs.
Percent of Days with Usage >= 4 Hours	20.0%
Percent of Days with Usage < 4 Hours	80.0%
Total Blower Time	2 days 20 hrs. 19 mins. 54 secs.
CPAP Summary	
Average Time in Large Leak Per Day	35 mins. 12 secs.
Average AHI	7.3
CPAP	18.0 cmH2O







Borat

Compliance Summary	
Date Range	3/1/2016 - 3/30/2016 (30 days)
Days with Device Usage	29 days
Days without Device Usage	1 day
Percent Days with Device Usage	96.7%
Cumulative Usage	7 days 13 hrs. 1 mins. 59 secs.
Maximum Usage (1 Day)	8 hrs. 27 mins.
Average Usage (All Days)	6 hrs. 2 mins. 3 secs.
Average Usage (Days Used)	6 hrs. 14 mins. 33 secs.
Minimum Usage (1 Day)	43 mins. 31 secs.
Percent of Days with Usage >= 4 Hours	80.0%
Percent of Days with Usage < 4 Hours	20.0%
Total Blower Time	7 days 13 hrs. 1 mins. 59 secs.
Auto CPAP Summary (Philips Respironics)	
Auto CPAP Mean Pressure	6.9 cmH2O
Auto CPAP Peak Average Pressure	8.9 cmH2C
Average Device Pressure <= 90% of Time	8.7 cmH20
Average Time in Large Leak Per Day	0 secs.
Average AHI	0.6

Device Settings as of	3/30/2016	
Device Mode	AutoCPAP - A-Flex	
Device Settings		
Parameter		Value
Min Pressure		5 cmH2O
Max Pressure		20 cmH2O
A-Flex Setting		3
Auto Off		Off
Auto On		On
View Optional Screens		Off
Ramp		Off
Mask Alert		Off
Mask Resistance		Off
Mask Resistance Lock		Off
Tubing Type		22
Tubing Type Lock		Off
Opti-Start		Off
Mask Reminder Period		Off
Change Humidifier Settings		Yes
Humidification Mode		System One
Humidifier Setting		Off
Instant Message Text		



Ó

Bertha

ResMed AirView	PROVERCE HEALTH AND SERVICES 6410 HE HULBEY STE 600 FORTUNG Gregory 1273 Phone 5002164683 Face 5002164109 Emit borbana Jaganofipovidance of Compliance F						
	Usage	.sport			03/44	5/2016 - 04/13	2/2016
	Usage days				03/1	30/30 days (
	>= 4 hours					30 days (
	< 4 hours						s (0%)
	Usage hours					222 hours 9 m	
	Average usage (total o	days)				7 hours 24 m	inutes
	Average usage (days	used)				7 hours 24 m	inutes
	Median usage (days u	used)				7 hours 26 m	inutes
	AirSense 10 AutoS	et	_		_		_
	Serial number					231512	34801
	Mode						CPAP
	Set pressure					12 c	mH2O
	EPR					Fi	ulltime
	EPR level						2
	Therapy						
	Leaks - L/min	Median:	0.9	95th percentile:	17.8	Maximum:	39.7
	Events per hour	AI:	37.8	HI:	1.1	AHI:	38.9
	Apnea Index	Central:	0.1	Obstructive:	35.5	Unknown:	2.1
	RERA Index						0.8
	Cheyne-Stokes respiration	n (average di	uration per i	night)	5 hor	irs 5 minutes	(69%)
					0.1101		
	Usage - hours						



Balthazar

Compliance Report

Usage				07/1	7/2016 - 08/15	/2016
Usage days					26/30 days	(87%)
>= 4 hours					9 days	(30%)
< 4 hours					17 days	(57%)
Usage hours					68 hours 26 m	inutes
Average usage (tota	il days)				2 hours 17 m	inutes
Average usage (day	s used)				2 hours 38 m	inutes
Median usage (days	used)				2 hours 35 m	inutes
AirSense 10 Auto	Set					
Serial number					231612	33830
Mode					A	utoSet
Min Pressure					5 c	mH20
Max Pressure					20 c	mH20
EPR					Fu	ulltime
EPR level						3
Therapy						
Pressure - cmH2O	Median:	5.4	95th percentile:	7.0	Maximum:	7.7
Leaks - L/min	Median:	31.3	95th percentile:	71.6	Maximum:	88.8
Events per hour	AI:	1.0	HI:	0.7	AHI:	1.7
Apnea Index	Central:	0.3	Obstructive:	0.4	Unknown:	0.3
						0.2

Usage - hours





CPAP Compliance Report

	Providence Health and Services 6410 NE Halsey Suite500		e 60 Series) (560P) (P102913701A13 V3.04)
	Portland, OR 97213		Therapy Data Summary
Patient:		Patient ID:	
		Home Phone:	
		Date of Birth:	
		Age:	
		Mask: QUATTRO FF	
Sleep Doctor:		-	
		Group/Practice:	
		Phone:	
		Fax	
		E-Mail Address:	
PCP:			
		Phone:	
Clinician:			
	6:		C-Flex+
Compliance I	nformation	3/18/2014 - 4/16/2014	feel the afference

Compliance Summary

Date Range	3/18/2014 - 4/16/2014 (30 days)
Days with Device Usage	27 days
Days without Device Usage	3 days
Percent Days with Device Usage	90.0%
Cumulative Usage	7 days 17 hrs. 37 mins. 41 secs.
Maximum Usage (1 Day)	8 hrs. 35 mins. 54 secs.
Average Usage (All Days)	6 hrs. 11 mins. 15 secs.
Average Usage (Days Used)	6 hrs. 52 mins. 30 secs.
Minimum Usage (1 Day)	2 hrs. 23 mins. 51 secs.
Percent of Days with Usage >= 4 Hours	86.7%
Percent of Days with Usage < 4 Hours	13.3%
Total Blower Time	7 days 17 hrs. 37 mins. 41 secs.

Sleep Therapy Statistics (Philips Respironics)

Average Time in Large Leak Per Day	3 mins, 2 secs,
Average AHI	1.6
CPAP Pressure	10.0 cmH2O





L		
	•	



Compliance Summary

Date Range	3/18/2014 - 4/16/2014 (30 days)
Days with Device Usage	27 days
Days without Device Usage	3 days
Percent Days with Device Usage	90.0%
Cumulative Usage	7 days 17 hrs. 37 mins. 41 secs.
Maximum Usage (1 Day)	8 hrs. 35 mins. 54 secs.
Average Usage (All Days)	6 hrs. 11 mins. 15 secs.
Average Usage (Days Used) 6 hrs. 52	
Minimum Usage (1 Day)	2 hrs. 23 mins. 51 secs.
Percent of Days with Usage >= 4 Hours	86.7%
Percent of Days with Usage < 4 Hours	13.3%
Total Blower Time	7 days 17 hrs. 37 mins. 41 secs.

Sleep Therapy Statistics (Philips Respironics)

Average Time in Large Leak Per Day	3 mins, 2 secs,	THE
Average AHI	1.6	UREGUN
CPAP Pressure	10.0 cmH2O	CLINIC



Bart	Device Settings as of		4/16/2014
	Device Mode Device Settings	CPAP - C-Flex+	CPAP Compliance Report
	Parameter		Value
	CPAP Pressure		10 cmH2O
	C-Flex+ Setting		2
	C-Flex+ Lock		Off
	Auto Off		Off
	Auto On		On
	View Optional Screens		On
	Ramp		On
	Ramp Time		20 minutes
	Ramp Start Pressure		4 cmH2O
	Mask Alert		Off
	Mask Resistance		Off
	Mask Resistance Lock		On
	Tubing Type		22
	Tubing Type Lock		On
	Mask Reminder Period		Off
	Change Humidifier Settings		No
	Instant Message Text		

Hours of Usage







Bethany

Compl	iance	Inforn	nation
-------	-------	--------	--------

3/19/2013 - 4/30/2013



Compliance Summary

Date Range	3/19/2013 - 4/30/2013 (43 days)
Days with Device Usage	16 days
Days without Device Usage	27 days
Percent Days with Device Usage	37.2%
Cumulative Usage	1 day 7 hrs. 56 mins. 26 secs.
Maximum Usage (1 Day)	4 hrs. 7 mins. 2 secs.
Average Usage (All Days)	44 mins. 34 secs.
Average Usage (Days Used)	1 hrs. 59 mins. 46 secs.
Minimum Usage (1 Day)	2 mins. 24 secs.
Percent of Days with Usage >= 4 Hours	2.3%
Percent of Days with Usage < 4 Hours	97.7%
Total Blower Time	1 day 14 hrs. 6 mins. 38 secs.

Sleep Therapy Statistics (Philips Respironics)

Average Time in Large Leak Per Day	5 mins.
Average AHI	3.2
CPAP Pressure	9.0 cmH2O





Bethany

Device Settings as of	4/30/2013	
Device Mode Device Settings	CPAP - C-Flex+	
Parameter		Value
CPAP Pressure		9 cmH2O
C-Flex+ Setting		1
C-Flex+ Lock		Off
Auto Off		Off
Auto On		On
View Optional Screens		On
Ramp		On
Ramp Time		20 minutes
Ramp Start Pressure		4 cmH2O
Mask Alert		Off
Mask Resistance		Off
Mask Resistance Lock		On
Tubing Type		22
Tubing Type Lock		On
Mask Reminder Period		Off
Change Humidifier Settings		No
Instant Message Text		

Hours of Usage







Bernie

Compliance Information

10/26/2013 - 11/24/2013

Compliance Summary

Date Range	10/26/2013 - 11/24/2013 (30 days)
Days with Device Usage	12 days
Days without Device Usage	18 days
Percent Days with Device Usage	40.0%
Cumulative Usage	1 day 6 hrs. 52 mins. 55 secs.
Maximum Usage (1 Day)	6 hrs. 48 mins. 49 secs.
Average Usage (All Days)	1 hrs. 1 mins. 45 secs.
Average Usage (Days Used)	2 hrs. 34 mins. 24 secs.
Minimum Usage (1 Day)	2 mins. 50 secs.
Percent of Days with Usage >= 4 Hours	6.7%
Percent of Days with Usage < 4 Hours	93.3%
Total Blower Time	2 days 17 hrs. 43 mins. 5 secs.

Sleep Therapy Statistics (Philips Respironics)

Average Time in Large Leak Per Day	25 mins.
Average AHI	2.1
CPAP Pressure	8.0 cmH2O

Hours of Usage







Auto-CPAP Download

Therapy	Data	Summary	y -	All	Data
---------	------	---------	-----	-----	------

Compliance Summary

Date Range	2/5/2014 - 3/6/2014 (30 days)
Days with Device Usage	28 days
Days without Device Usage	2 days
Percent Days with Device Usage	93.3%
Cumulative Usage	5 days 20 hrs. 13 mins. 46 secs.
Maximum Usage (1 Day)	7 hrs. 11 mins. 53 secs.
Average Usage (All Days)	4 hrs. 40 mins. 27 secs.
Average Usage (Days Used)	5 hrs. 29 secs.
Minimum Usage (1 Day)	2 hrs. 37 mins. 35 secs.
Percent of Days with Usage >= 4 Hours	80.0%
Percent of Days with Usage < 4 Hours	20.0%
Total Blower Time	5 days 20 hrs. 56 mins. 46 secs.

Auto CPAP Summary (Philips Respironics)

Auto CPAP Mean Pressure	6.6 cmH2O
Auto CPAP Peak Average Pressure	9.2 cmH2O
Average Device Pressure <= 90% of Time	8.6 cmH2O
Average Time in Large Leak Per Day	9 secs.
Average AHI	4.1

Device Settings as of	3/6/2014	
Device Mode	AutoCPAP - A-Flex	
Device Settings		
Parameter		Value
Min Pressure		5 cmH2O
Max Pressure		15 cmH2O
A-Flex Setting		3
A-Flex Lock		Off
Auto Off		Off
Auto On		On
View Optional Screens		On
Ramp		On
Ramp Time		10 minutes
Ramp Start Pressure		4 cmH2O
Mask Alert		Off
Mask Resistance		1
Mask Resistance Lock		Off
Tubing Type		22
Tubing Type Lock		Off
Mask Reminder Period		Off
Change Humidifier Settings		Yes
Humidification Mode		System One
Humidifier Setting		5
Instant Message Text		





Auto-CPAP Download

reprua	ry, 2014
2/5/2014	4:34 6:07/6:07
2/6/2014	6:30 7:04/7:04
2/7/2014	4:26 5:32/5:32
Saturday	2:51 2:51/2:51
Sunday	54 3121 6:29/6:29
2/10/2014	4:18/4:18
2/11/2014 2	7 4:46/4:46
2/12/2014	0:00/0:00
2/13/2014	4:58 5:40/5:40
2/14/2014	4:16/4:16
Saturday	5:35/5:35
Sunday	4:49/4:49
2/17/2014	3:39 4:11/4:11
2/18/2014	4:00 4:41/4:41
2/19/2014	5:06 6:43/6:43
2/20/2014	6:59/6:59
2/21/2014	642 7:12/7:12
Saturday	5:25/5:25
Sunday	3:28 3:35/3:35
2/24/2014	2:38/3:09
2/25/2014	3:13 4:26/4:26
2/26/2014	3:35 4:45/4:45
2/27/2014	0:00/0:00
2/28/2014	4:10/4:10

Patterns of Use







Auto-CPAP Download







Auto-CPAP Download

Summary of Daily Events Per Hour

Total AHI: 4.0

2/5/201 P													20				
۲	4	5	0	/	8	9	10	11	12	13	14	15	16	1/	18	19	20
MaP	0.2	3,440.5	1,794.0	795.3	773.7	661.3	350.8	229.1	219.4	79.4	48.6	21.5	0.0	0.0	0.0	0.0	0.0
%	0.0	40.9	21.3	9.5	9.2	7.9	4.2	2.7	2.6	0.9	0.6	0.3	0.0	0.0	0.0	0.0	0.0
FL	0.0	0.7	0.5	0.9	0.8	0.3	0.7	1.0	0.8	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
V5	0.0	3.3	4.8	9.6	8.7	7.6	8.4	13.1	8.8	15.1	11.1	41.8	0.0	0.0	0.0	0.0	0.0
OA	0.0	1.3	1.5	1.7	2.2	2.2	1.4	2.9	2.2	3.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0
CA	0.0	0.1	0.1	0.5	0.2	0.4	0.5	0.8	1.6	0.8	1.2	2.8	0.0	0.0	0.0	0.0	0.0
H	0.0	1.1	2.0	4.3	4.6	4.5	1.0	0.5	0.5	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0
RE	0.0	0.2	0.6	1.3	0.9	0.8	0.5	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AHI	0.0	2.5	3.6	6.5	7.0	7.1	2.9	4.2	4.3	3.8	4.9	2.8	0.0	0.0	0.0	0.0	0.0
						90%		-				-					-

Legend P - Pressure, MaP - Minutes at Pressure, % - Percent of Night, FL - Flow Limitation, VS - Vibratory Snore, H - Hypopnea, OA - Obstructed Airway Apnea, CA - Clear Airway Apnea, RE - RERA, AHI - Apnea/Hypopnea Index

Auto CPAP Time at Pressure

2/5/2014 - 3/6/2014





